PLX Protalix BioTherapeutics Inc

Price (delayed)

$2.36

Market cap

$190.15M

P/E Ratio

12.42

Dividend/share

N/A

EPS

$0.19

Enterprise value

$156.92M

?
Relative Growth: Rel. Growth: 89
Relative Strength: Rel. Strength: 63
Relative Valuation: Rel. Valuation: 93
Relative Profitability: Rel. Profitability: 98

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies ...

Highlights
The gross profit has surged by 108% since the previous quarter and by 79% year-on-year
Protalix BioTherapeutics's equity has increased by 49% YoY and by 39% QoQ
PLX's debt has soared by 62% YoY

Key stats

What are the main financial stats of PLX

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-9.92%
1 week
-3.28%
1 month
-1.26%
1 year
46.58%
YTD
31.11%
QTD
1.29%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$76.38M
Gross profit
$53.44M
Operating income
$19.79M
Net income
$15.33M
Gross margin
70%
Net margin
20.1%
The gross profit has surged by 108% since the previous quarter and by 79% year-on-year
Protalix BioTherapeutics's revenue has increased by 45% from the previous quarter and by 28% YoY
Protalix BioTherapeutics's gross margin has increased by 43% QoQ and by 40% YoY

Price vs fundamentals

How does PLX's price correlate with its fundamentals

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
12.42
P/B
2.83
P/S
2.47
EV/EBIT
7.54
EV/EBITDA
7.03
EV/Sales
2.05
Protalix BioTherapeutics's equity has increased by 49% YoY and by 39% QoQ
Protalix BioTherapeutics's revenue has increased by 45% from the previous quarter and by 28% YoY
PLX's price to sales (P/S) is 30% higher than its 5-year quarterly average of 1.9 and 2.9% higher than its last 4 quarters average of 2.4

Efficiency

How efficient is Protalix BioTherapeutics business performance
PLX's return on sales has surged by 178% year-on-year
Protalix BioTherapeutics's return on equity has surged by 168% YoY
The return on invested capital has surged by 131% year-on-year

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 191% greater than its total liabilities
PLX's total assets is up by 38% year-on-year and by 24% since the previous quarter
Protalix BioTherapeutics's quick ratio has increased by 33% QoQ and by 23% YoY
PLX's debt is 87% less than its equity
PLX's debt has soared by 62% YoY
Protalix BioTherapeutics's equity has increased by 49% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.